company background image
ALK B logo

ALK-Abelló CPSE:ALK B Stock Report

Last Price

DKK 153.90

Market Cap

DKK 33.6b

7D

-1.0%

1Y

39.0%

Updated

30 Jan, 2025

Data

Company Financials +

ALK-Abelló A/S

CPSE:ALK B Stock Report

Market Cap: DKK 33.6b

ALK B Stock Overview

Operates as an allergy solutions company in Europe, North America, and internationally. More details

ALK B fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 24.9% below our estimate of its fair value

Earnings are forecast to grow 27.25% per year

Earnings grew by 85.1% over the past year

Risk Analysis

No risks detected for ALK B from our risk checks.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
Analyst Price Target
Consensus Narrative from 5 Analysts

Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings

Key Takeaways The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward. Continuous international growth in tablet sales and cost-saving measures indicate sustained revenue growth and improved operational efficiency.
View narrative
DKK 179.20
FV
14.1% undervalued intrinsic discount
11.50%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Updated narrative

My Notes

Capture your thoughts, links and company narrative

ALK-Abelló A/S Competitors

H. Lundbeck

CPSE:HLUN B

DKK 40.9b

Novo Nordisk

CPSE:NOVO B

DKK 2.7t

ChemoMetec

CPSE:CHEMM

DKK 8.7b

Genmab

CPSE:GMAB

DKK 88.6b

Price History & Performance

Summary of share price highs, lows and changes for ALK-Abelló
Historical stock prices
Current Share PriceDKK 153.90
52 Week HighDKK 185.60
52 Week LowDKK 110.20
Beta0.62
1 Month Change-3.27%
3 Month Change-5.93%
1 Year Change39.02%
3 Year Change11.36%
5 Year Change53.13%
Change since IPO350.66%

Recent News & Updates

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Dec 18
ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Recent updates

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Dec 18
ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Results: ALK-Abelló A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 17
Results: ALK-Abelló A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Nov 10
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Oct 10
Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Analysts Have Made A Financial Statement On ALK-Abelló A/S' (CPH:ALK B) Second-Quarter Report

Aug 25
Analysts Have Made A Financial Statement On ALK-Abelló A/S' (CPH:ALK B) Second-Quarter Report

What You Can Learn From ALK-Abelló A/S' (CPH:ALK B) P/E

Aug 12
What You Can Learn From ALK-Abelló A/S' (CPH:ALK B) P/E

Is ALK-Abelló (CPH:ALK B) Using Too Much Debt?

Jun 25
Is ALK-Abelló (CPH:ALK B) Using Too Much Debt?

A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

Jun 07
A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

May 05
ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Apr 27
ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 06
ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Jan 19
ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

Jan 01
With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

Sep 09
Is ALK-Abelló (CPH:ALK B) A Risky Investment?

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Jun 11
ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

May 24
Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Mar 12
ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 17
ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

Jan 30
Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

Dec 05
ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

Nov 11
Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Sep 01
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Aug 05
Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Shareholder Returns

ALK BDK PharmaceuticalsDK Market
7D-1.0%4.4%2.4%
1Y39.0%-20.7%-13.0%

Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned -20.7% over the past year.

Return vs Market: ALK B exceeded the Danish Market which returned -13% over the past year.

Price Volatility

Is ALK B's price volatile compared to industry and market?
ALK B volatility
ALK B Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.7%
10% most volatile stocks in DK Market10.6%
10% least volatile stocks in DK Market2.8%

Stable Share Price: ALK B has not had significant price volatility in the past 3 months compared to the Danish market.

Volatility Over Time: ALK B's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19232,795Peter Hallingwww.alk.net

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

ALK-Abelló A/S Fundamentals Summary

How do ALK-Abelló's earnings and revenue compare to its market cap?
ALK B fundamental statistics
Market capDKK 33.60b
Earnings (TTM)DKK 785.00m
Revenue (TTM)DKK 5.38b

43.4x

P/E Ratio

6.3x

P/S Ratio

Is ALK B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALK B income statement (TTM)
RevenueDKK 5.38b
Cost of RevenueDKK 1.94b
Gross ProfitDKK 3.44b
Other ExpensesDKK 2.66b
EarningsDKK 785.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 19, 2025

Earnings per share (EPS)3.55
Gross Margin63.96%
Net Profit Margin14.58%
Debt/Equity Ratio3.7%

How did ALK B perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 18:02
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALK-Abelló A/S is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Alexandru CogutBryan Garnier & Co
Jesper IlsoeCarnegie Investment Bank AB